| scholarly article | Q13442814 |
| P356 | DOI | 10.1186/1743-422X-11-142 |
| P8608 | Fatcat ID | release_yi4bxeirkjfh5b36mvhug7wkjy |
| P932 | PMC publication ID | 4254404 |
| P698 | PubMed publication ID | 25107552 |
| P2093 | author name string | Guoming Li | |
| Bing Hu | |||
| Yuanding Chen | |||
| Xuhua Guan | |||
| Yongzhong Jiang | |||
| Jianbo Zhan | |||
| Zhizheng Fang | |||
| Jiawei Jiang | |||
| P2860 | cites work | Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo | Q40868890 |
| Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults | Q44982507 | ||
| CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. | Q45399869 | ||
| Induction of balanced immunity in BALB/c mice by vaccination with a recombinant fusion protein containing a respiratory syncytial virus G protein fragment and a CTL epitope | Q45423911 | ||
| Co-immunization of BALB/c mice with recombinant immunogens containing G protein fragment and chimeric CTL epitope of respiratory syncytial virus induces enhanced cellular immunity and high level of antibody response | Q45453606 | ||
| Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate | Q45723621 | ||
| Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes | Q45725679 | ||
| Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma | Q45731094 | ||
| Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia | Q45757916 | ||
| [RSV infection course in infants and young children during hospitalization] | Q84079746 | ||
| The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. | Q30306426 | ||
| The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. | Q30437797 | ||
| Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection | Q30442832 | ||
| Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. | Q33645414 | ||
| Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for va | Q33707803 | ||
| Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant | Q33738521 | ||
| Genetic variability of respiratory syncytial viruses (RSV) prevalent in Southwestern China from 2006 to 2009: emergence of subgroup B and A RSV as dominant strains | Q33769665 | ||
| Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge | Q33783066 | ||
| The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin | Q33863111 | ||
| Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness | Q33883942 | ||
| Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. | Q34151000 | ||
| Respiratory syncytial virus infection in elderly and high-risk adults | Q34414401 | ||
| Human Respiratory Syncytial Virus in Children with Acute Respiratory Tract Infections in China | Q34489610 | ||
| The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes | Q34651258 | ||
| Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection | Q35632362 | ||
| The future of respiratory syncytial virus vaccine development | Q35632372 | ||
| Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus | Q35872191 | ||
| New generation live vaccines against human respiratory syncytial virus designed by reverse genetics | Q36237057 | ||
| Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics | Q36276526 | ||
| Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. | Q36684360 | ||
| Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. | Q36961083 | ||
| The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines | Q37384009 | ||
| Strategic priorities for respiratory syncytial virus (RSV) vaccine development | Q37572640 | ||
| Current progress on development of respiratory syncytial virus vaccine. | Q37869553 | ||
| Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children | Q38305707 | ||
| A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis | Q39260328 | ||
| Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents | Q39588511 | ||
| Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene | Q39603697 | ||
| A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats | Q39696619 | ||
| Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women | Q40555244 | ||
| Rescue of bovine respiratory syncytial virus from cloned cDNA: entire genome sequence of BRSV strain A51908. | Q40766426 | ||
| P304 | page(s) | 142 | |
| P577 | publication date | 2014-08-08 | |
| P1433 | published in | Virology Journal | Q7934868 |
| P1476 | title | Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus | |
| P478 | volume | 11 |
| Q92219117 | A Contemporary View of Respiratory Syncytial Virus (RSV) Biology and Strain-Specific Differences |
| Q64938927 | A Reverse Genetics System for Cypovirus Based on a Bacmid Expressing T7 RNA Polymerase. |
| Q89860924 | Engineering of Live Chimeric Vaccines against Human Metapneumovirus |
| Q26795706 | Rift Valley fever virus: A review of diagnosis and vaccination, and implications for emergence in Europe |
| Q64252092 | The One Health Approach is Necessary for the Control of Rift Valley Fever Infections in Egypt: A Comprehensive Review |
Search more.